IP Library › Granted Patent US 12,234,210
Granted Patent B2
US 12,234,210 · App. 18/304,202 · Granted Feb 25, 2025

Synthesis of nirogacestat

Inventors: Kristin Patterson (Stamford, CT); Mark Hatcher (Stamford, CT)
Assignee: SPRINGWORKS THERAPEUTICS, INC.
C07D233/88C07C227/26C07D263/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,234,210
App. No.
18/304,202
Granted
Feb 25, 2025
Kind
B2
Abstract

The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (“nirogacestat”).

Claims (16)

1. A composition comprising 98.0% to 99.9% by weight of Compound 1 or a salt thereof prepared by a process comprising the steps of combining Compound 10

with Compound 11

to form Compound 1, and optionally treating Compound 1 with an acid in a solvent to form a salt of Compound 1

wherein the composition comprises at least one of:

(a) 0.7% to 0.01% by weight of Compound 2 having the formula

or a pharmaceutically acceptable salt thereof,

(b) 0.7% to 0.01% by weight of Compound 3 having the formula

or a pharmaceutically acceptable salt thereof, or

(c) 0.7% to 0.01% by weight of Compound 4 having the formula

or a pharmaceutically acceptable salt thereof.

2. The composition of claim 1 , wherein the composition comprises 0.7% to 0.01% by weight of Compound 2

or a pharmaceutically acceptable salt thereof.

3. The composition of claim 1 , wherein the composition comprises 0.7% to 0.01% by weight of Compound 3 having the formula

or a pharmaceutically acceptable salt thereof.

4. The composition of claim 1 , wherein the composition comprises 0.7% to 0.01% by weight of Compound 4 having the formula

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2024
From: PATTERSON, KRISTIN; HATCHER, MARK
To: SPRINGWORKS THERAPEUTICS, INC.
Reel/Frame 069362/0438 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2023
From: PATTERSON, KRISTIN; HATCHER, MARK
To: SPRINGWORKS THERAPEUTICS, INC.
Reel/Frame 064613/0218 →
Continuity (3)
Continuation PCTUS2022075839 · Sep 1, 2022
Provisional Application 63239696 · Sep 1, 2021
Related Publication 20230312480A1 · Oct 5, 2023
References Cited (99)
US 7342118B2 · Brodney et al. · 2008 [cited by applicant]
US 7795447B2 · Brodney et al. · 2010 [cited by applicant]
US 7951958B2 · Brodney et al. · 2011 [cited by applicant]
US 10590087B1 · Greer et al. · 2020 [cited by applicant]
US 10710966B1 · Greer et al. · 2020 [cited by applicant]
US 10941118B2 · Greer et al. · 2021 [cited by applicant]
US 11504354B1 · Patterson · 2022 [cited by examiner]
US 11612588B1 · Patterson · 2023 [cited by examiner]
US 11807611B2 · Patterson · 2023 [cited by examiner]
US 11844780B2 · Patterson · 2023 [cited by examiner]
US 20050107381A1 · Chen · 2005 [cited by applicant]
US 20050215610A1 · Brodney · 2005 [cited by examiner]
US 20050222219A1 · Chen · 2005 [cited by applicant]
US 20100184737A1 · Brodney · 2010 [cited by applicant]
US 20160354382A1 · Pajvani · 2016 [cited by applicant]
US 20180194773A1 · Ban et al. · 2018 [cited by applicant]
US 20180214553A1 · Berenson · 2018 [cited by applicant]
US 20190161553A1 · Sather et al. · 2019 [cited by applicant]
US 20190359727A1 · Riddell et al. · 2019 [cited by applicant]
US 20190367628A1 · Abujoub et al. · 2019 [cited by applicant]
US 20200055948A1 · Daley et al. · 2020 [cited by applicant]
US 20200179511A1 · Daley et al. · 2020 [cited by applicant]
US 20210040045A1 · Greer et al. · 2021 [cited by applicant]
US 20210269407A1 · Greer et al. · 2021 [cited by applicant]
US 20230049311A1 · Cheng et al. · 2023 [cited by applicant]
US 20230087828A1 · Cheng et al. · 2023 [cited by applicant]
US 20230088856A1 · Patterson et al. · 2023 [cited by applicant]
US 20230089434A1 · Patterson et al. · 2023 [cited by applicant]
US 20230090557A1 · Patterson et al. · 2023 [cited by applicant]
US 20230091097A1 · Patterson et al. · 2023 [cited by applicant]
US 20230091415A1 · Patterson et al. · 2023 [cited by applicant]
US 20230112444A1 · Balakumaran et al. · 2023 [cited by applicant]
US 20230121547A1 · Shearer et al. · 2023 [cited by applicant]
WO WO0049037A1 · 2000 [cited by applicant]
WO WO0210141A1 · 2002 [cited by applicant]
WO WO2005092864A1 · 2005 [cited by applicant]
WO WO2013153391A1 · 2013 [cited by applicant]
WO WO2016120216A1 · 2016 [cited by applicant]
WO WO2016166630A1 · 2016 [cited by applicant]
WO WO2018045273A2 · 2018 [cited by applicant]
WO WO2018151836A1 · 2018 [cited by applicant]
WO WO2018201051A1 · 2018 [cited by applicant]
WO WO2018201056A1 · 2018 [cited by applicant]
WO WO2019053727A1 · 2019 [cited by applicant]
WO WO2019090364A1 · 2019 [cited by applicant]
WO WO2020092848A2 · 2020 [cited by applicant]
WO WO2020092854A2 · 2020 [cited by applicant]
WO WO2020208572A1 · 2020 [cited by examiner]
WO WO2021029854A1 · 2021 [cited by applicant]
WO WO2021146604A1 · 2021 [cited by applicant]
WO WO2021183934A1 · 2021 [cited by applicant]
WO WO2023039475A1 · 2023 [cited by applicant]
Brodney, et al. Bioorganic & Medicinal Chemistry Letters 21 (2011) 2637-2640. [cited by examiner]
Brodney, et al. Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as y-secretase inhibitors: Discovery of PF-3084014, (Bioorganic & Medicinal Chemistry Letters 21, 2637-2640)… [cited by examiner]
Robinson, Control of Genotoxic Impurities in Active Pharmaceutical Ingredients: A review and Perspective (Organic Process Research & Development, 14, 946-959). (Year: 2010). [cited by examiner]
Jadhav et al. A Comprehensive Review for the Learners and Users: Preparative High Performance Liquid Chromatography, (IJCPA, 1(3), 121-129). (Year: 2014). [cited by examiner]
Aurora Building Blocks, Chemical Abstracts Service, Accession No. 1962925-29-6, accessed through STN database on Feb. 21, 2020, American Chemical Society, United States, 1 page (published Feb. 21, 2019). [cited by applicant]
Berge, S.M., et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences 66(1):1-19, Elsevier, United States (Jan. 1977). [cited by applicant]
Bierer, B.E., et al., “Cyclosporin A and FK506: Molecular Mechanisms of Immunosuppression and Probes for Transplantation Biology,” Current Opinion in Immunology 5(5):763-773, Elsevier, United Kingdom (Oct. 1993). [cited by applicant]
Bird, R.E., et al., “Single-chain Antigen-binding Proteins,” Science 242(4877):423-426, Association for the Advancement of Science, United States (Oct. 1988). [cited by applicant]
Co-pending U.S. Appl. No. 17/995,031, inventors Patterson, K., et al., filed Sep. 8, 2022 (Not yet Published). [cited by applicant]
CAS Registry No. 1290543-63-3, Substance Detail, retrieved from SciFinder CAS, accessed on Aug. 29, 2022, 3 pages. [cited by applicant]
ClinicalTrials.gov, “A Study Evaluating PF-03084014 in Patients With Advanced Breast Cancer With or Without Notch Alterations,” NCT02299635, accessed at https://clinicaltrials.gov/ct2/show/NCT02299635?term=03084014&rank… [cited by applicant]
ClinicalTrials.gov, “A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors,” NCT02462707, accessed at https://clinicaltrials.gov/ct2/show/NCT02462707?term=NCT02462707&draw=2&rank=1, accessed on Nov. 8, … [cited by applicant]
ClinicalTrials.gov, “A Study Evaluating the PF-03084014 in Combination With Docetaxel in Patients With Advanced Breast Cancer,” NCT01876251, accessed at https://clinicaltrials.gov/ct2/show/NCT01876251?term=03084014&rank… [cited by applicant]
ClinicalTrials.gov, “A Trial in Patients With Advanced Cancer and Leukemia,” NCT00878189, accessed at https://clinicaltrials.gov/ct2/show/NCT00878189?term=03084014&rank=9, accessed on Nov. 8, 2022, 16 pages. [cited by applicant]
ClinicalTrials.gov, “Biomarker Research Study for PF-03084014 in Chemoresistant Triple-negative Breast Cancer (RHEA),” NCT02338531, accessed at https://clinicaltrials.gov/ct2/show/NCT02338531?term=03084014&rank=5, acces… [cited by applicant]
ClinicalTrials.gov, “Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies,” NCT02955446, accessed at https://clinicaltrials.gov/ct2/show/NCT02955446?term=03084014&rank=7, accesse… [cited by applicant]
ClinicalTrials.gov, “Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma,” NCT02137564, accessed at https://clinicaltrials.gov/ct2/show/NCT02137564?term=03084014&rank=2, access… [cited by applicant]
ClinicalTrials.gov “Nirogacestat for Adults with Desmoid Tumor/Aggressive Fibromatosis (DT/AF) (DeFi),” NCT03785964, accessed at https://clinicaltrials.gov/ct2/show/NCT03785964?term=nirogacestat&rank=1, accessed on Nov.… [cited by applicant]
ClinicalTrials.gov, “Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis,” NCT01981551, accessed at https://clinicaltrials.gov/ct2/show/NCT01981551?term=0308… [cited by applicant]
ClinicalTrials.gov, “Study of PF-03084014 in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies,” NCT02109445, accessed… [cited by applicant]
ClinicalTrials.gov, “Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (Dreamm 5),” NCT04126200, access… [cited by applicant]
ClinicalTrials.gov, “PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma,” NCT03269136, accessed at https://clinicaltrials.gov/ct2/show/NCT03269136?term=NCT… [cited by applicant]
ClinicalTrials.gov, “Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (Universal) (Universal),” NCT04093596, accessed at https://clinicaltrials.gov/ct2… [cited by applicant]
Cowan, A., et al., “Efficacy and Safety of Fully Human Bema CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bema Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma,” Bloo… [cited by applicant]
Eastman, S., et al., “Synergistic Activity of Belantamab Mafodotin (anti-BCMA immune-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bema-Expressing Cancer Cell Lines,” Blood 134(S1):4401, American Society of… [cited by applicant]
Henderson, D.J., et al., “Comparison of the Effects of FK-506, Cyclosporin A and Rapamycin on IL-2 Production,” Immunology 73(3):316-321, Blackwell Scientific Publications, United Kingdom (Jul. 1991). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/045948, European Patent Office, Netherlands, mailed Jul. 6, 2020, 9 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/013705, European Patent Office, Netherlands, mailed May 7, 2021, 11 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/022177, European Patent Office, Netherlands, mailed Jun. 24, 2021, 13 pages. [cited by applicant]
Kummar, S., et al., “Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis),” J. Clin. Oncology 35(14):1561-9, American Society of Clinical Oncology, United St… [cited by applicant]
Liu, J., et al., “Inhibition of T Cell Signaling by Immunophilin-ligand Complexes Correlates With Loss of Calcineurin Phosphatase Activity,” Biochemistry 31(16):3896-3901, American Chemical Society, United States (Apr. … [cited by applicant]
Millipore Sigma, “PF-03084014 hydrobromide,” SigmaAldrich.com, accessed at https://www.sigmaaldrich.com/catalog/product/sigma/pz0298?lang=en®ion=US, accessed on Nov. 8, 2022, 4 pages. [cited by applicant]
Nazarian, A.A., et al., “Characterization of Bispecific T-cell Engager (BiTE) Antibodies With a High-capacity T-cell Dependent Cellular Cytotoxicity (TDCC) Assay,” Journal of Biomolecular Screening 20(4):519-527, Sage P… [cited by applicant]
Pont, M.J., et al., “γ-Secretase Inhibition Increases Efficacy of BCMA-specific Chimeric Antigen Receptor T Cells in Multiple Myeloma,” Blood 134(19):1585-1597, Elsevier, United States (Nov. 2019). [cited by applicant]
[cited by applicant]
Saif, M.A., et al., “In vivo T-cell Depletion Using Alemtuzumab in Family and Unrelated Donor Transplantation for Pediatric non-Malignant Disease Achieves Engraftment with Low Incidence of Graft vs. Host Disease,” Pedia… [cited by applicant]
Shang, H., et al., “Targeting the Notch Pathway: A Potential Therapeutic Approach for Desmoid Tumors,” Cancer 121(22):4088-96, Wiley-Liss, United States (2015). [cited by applicant]
Silverman, R.B., pp. 29-32 in [cited by applicant]
Sommer, C., et al., “Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma,” Molecular Therapy 27(6):1126-1138, Cell Press, United States (Jun. 2019). [cited by applicant]
Takahashi, T., et al., “Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases,” Pediatr. Blood Cancer 67(10):e28636, Wiley, United State… [cited by applicant]
The United States Pharmacopeia—National Formulary, “941 X-ray Diffraction,” 23rd Edition, NF-18, pp. 1843-1844, The United States Pharmacopeial Convention, United States (1995). [cited by applicant]
UniProtKB, “TNR17_HUMAN,” Accession No. Q02223, UniProt.org, accessed at https://www.uniprot.org/uniprotkb/Q02223/entry, on Nov. 7, 2022, 6 pages. [cited by applicant]
Wei, P., et al., “Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design,” Molecular Cancer Therapeutics 9(6):1618-28, Ame… [cited by applicant]
Pub Chem AKOS03764977, 2005. [cited by applicant]
International Search and Written Opinion issued in PCT/US2022/075839 on Jan. 27, 2023. [cited by applicant]
PubChem-SID-340503698, Modify Date: Nov. 20, 2020 (Nov. 20, 2020), p. 2, figure, this is a purchasable chemical. [cited by applicant]
PubChem-SID-441886460, Modify Date: Jul. 20, 2021 (Jul. 20, 2021), p. 2, figure, this is a purchasable chemical. [cited by applicant]
Cited By (1)
US 12,599,587